REG - Creo Medical Group - Open Offer Launch, Posting of Circular & GM Notice

Creo MedicalAnnouncement

16/08/2021 15:35

RNS Number : 8001I
  
Creo Medical Group PLC
  
16 August 2021
  
 

THIS ANNOUNCEMENT, INLCUDING THE INFORMATION CONTAINED IN IT, IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION, DISTRIBUTION OR FORWARDING, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, THE REPUBLIC OF SOUTH AFRICA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.
 
FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION.
 
LEI: 213800H188ZDCWWXFA21
 
 
16 August 2021
 
Creo Medical Group plc
("Creo" or the "Company")
 
Launch of Open Offer, Posting of Circular
and
Notice of General Meeting
 
 
The Company is pleased to announce that, further to the announcement made on 12 August 2021 (RNS No: 5145I ) regarding the Fundraising (the "Launch Announcement"), it is proposing to raise up to approximately £5.07 million (before expenses) through an Open Offer pursuant to which Qualifying Shareholders will have an opportunity to subscribe for an aggregate of 2,775,896 Open Offer Shares at an Offer Price of 182.5 pence per Open Offer Share.
 
Pursuant to the Open Offer, Qualifying Shareholders will be given the opportunity to subscribe for:
 
1 Open Offer Share for every 58 Existing Ordinary Shares
 
held by Qualifying Shareholders at the Record Date and so on in proportion for any other number of Existing Shares then held.
 
Any Open Offer Shares not subscribed for by Qualifying Shareholders will be available to Qualifying Shareholders under the Excess Application Facility and as such, Qualifying Shareholders seeking to limit their dilution from the Placing can also request additional Open Offer Shares ("Excess Shares") under the Excess Application Facility. The Open Offer is not being underwritten. 
 
The Open Offer is conditional upon, among other things (i) the Resolutions being duly passed by Shareholders at the General Meeting and (ii) Admission having become effective at or before 8.00 a.m. on 7 September 2021 (or such later time and/or date as Cenkos may agree with the Company not being later than 8.00 a.m. on 14 September 2021).
 
Posting of Circular 
The Company also confirms that a circular, which contains further details regarding the Open Offer and a notice convening the General Meeting (the "Circular"), has been posted today to Qualifying Shareholders, along with the Application Form (where applicable). The Circular will also be made available on the Company's website: www.creomedical/investors.
 
Notice of General Meeting
The General Meeting has been convened for 6 September 2021 at 10 a.m. at the offices of Osborne Clarke LLP, 2 Temple Back East, Temple Quay, Bristol BS1 6EG.
 
Capitalised terms used in this announcement have the meanings given to them in the Circular unless the context provides otherwise.
 
 




Creo Medical Group plc


www.creomedical.com




Richard Rees (CFO)


+44 (0)1291 606 005




 


 




Cenkos Securities plc


+44 (0)20 7397 8900




Stephen Keys / Camilla Hume (NOMAD)


 




Michael Johnson / Russell Kerr (Sales)


 




 


 




Walbrook PR Ltd


Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com




Paul McManus / Lianne Cawthorne 


Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303 



 
 
 
 



 
Expected Timetable for the Fundraising
 




 
Announcement of the Fundraising


2021
12 August
 




Record Date for entitlement under the Open Offer


12 August
 




Announcement of the results of the Placing


13 August
 




Publication of the Circular, Proxy Form and, to Qualifying Non-Crest Shareholders, the Application Form


16 August
 
 




Ex-entitlement date of the Open Offer


16 August
 




Open Offer Entitlements and Excess Open Offer Entitlements credited to stock accounts in CREST of Qualifying CREST Shareholders


17 August
 
 




Latest recommended time and date for requested withdrawal of Basic Open Offer Entitlements from CREST


4.30 p.m. on 27 August
 
 




Latest time and date for depositing Open Offer Entitlements in CREST


3.00 p.m. on 31 August
 




Latest time and date for splitting of Application Forms under the Open Offer


3.00 p.m. on 1 September
 




Latest time and date for receipt of Forms of Proxy and CREST voting instructions


10.00 a.m. on 2 September
 




Latest time and date for receipt of Application Forms and payment in full under the Open Offer and settlement of relevant CREST instructions (as appropriate)


11.00 a.m. on 3 September
 
 




General Meeting


10.00 a.m. on 6 September
 




Results of the General Meeting and the Open Offer announced


6 September
 




Admission of the New Ordinary Shares to trading on AIM and commencement of dealings


8.00 a.m. on 7 September
 
 




Where applicable, expected date for CREST accounts to be credited in respect of New Ordinary Shares in uncertificated form


7 September
 
 




Where applicable, expected date for despatch of definitive share certificates for New Ordinary Shares in certificated form


21 September




 


 




 


 




 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
FURGPUUWRUPGGCQ